Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting

Giuseppe Procopio, Lisa Derosa, Angela Gernone, Franco Morelli, Teodoro Sava, Fable Zustovich, Ugo De Giorgi, Vittorio Ferrari, Roberto Sabbatini, Donatello Gasparro, Alessandra Felici, Luciano Burattini, Nicola Calvani, Giovanni Lo Re, Giuseppe Banna, Maria Pia Brizzi, Mimma Rizzo, Libero Ciuffreda, Roberto Iacovelli, Francesco FerraùEleonora Taibi, Sergio Bracarda, Camillo Porta, Enzo Galligioni, Antonio Contu

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Aim: The Italian Retrospective Analysis of Sorafenib as First or Second Target Therapy study assessed the efficacy and safety of sorafenib in metastatic renal cell carcinoma patients treated in the community. Patients & methods: Patients receiving first- or second-line single-agent sorafenib between January 2008 and December 2010 were eligible. Retrospective data collection started in 2012 and covers at least 1-year follow-up. The primary end point was overall survival (OS). Results: Median OS was 17.2 months (95% CI: 15.5-19.6): 19.9 months (95% CI: 15.9-25.3) in patients treated with first-line sorafenib and 16.3 months (95% CI: 13.1-18.2) with second-line sorafenib. Overall median (95% CI) progression-free survival was 5.9 months (95% CI: 4.9-6.7): 6.6 (95% CI: 4.9-9.3) and 5.3 months (95% CI: 4.3-6.0) in first- and second-line patients, respectively. Conclusion: The efficacy and safety of sorafenib in routine community practice was generally good, especially in relation to OS in patients treated in the second line, where results were similar to those seen in recent prospective clinical trials.

Original languageEnglish
Pages (from-to)1741-1750
Number of pages10
JournalFuture Oncology
Volume10
Issue number10
DOIs
Publication statusPublished - Aug 1 2014

Fingerprint

Renal Cell Carcinoma
Survival
Therapeutics
Safety
Disease-Free Survival
sorafenib
Clinical Trials

Keywords

  • community practice
  • renal cell carcinoma
  • second-line treatment
  • sorafenib
  • targeted agents
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. / Procopio, Giuseppe; Derosa, Lisa; Gernone, Angela; Morelli, Franco; Sava, Teodoro; Zustovich, Fable; De Giorgi, Ugo; Ferrari, Vittorio; Sabbatini, Roberto; Gasparro, Donatello; Felici, Alessandra; Burattini, Luciano; Calvani, Nicola; Lo Re, Giovanni; Banna, Giuseppe; Pia Brizzi, Maria; Rizzo, Mimma; Ciuffreda, Libero; Iacovelli, Roberto; Ferraù, Francesco; Taibi, Eleonora; Bracarda, Sergio; Porta, Camillo; Galligioni, Enzo; Contu, Antonio.

In: Future Oncology, Vol. 10, No. 10, 01.08.2014, p. 1741-1750.

Research output: Contribution to journalArticle

Procopio, G, Derosa, L, Gernone, A, Morelli, F, Sava, T, Zustovich, F, De Giorgi, U, Ferrari, V, Sabbatini, R, Gasparro, D, Felici, A, Burattini, L, Calvani, N, Lo Re, G, Banna, G, Pia Brizzi, M, Rizzo, M, Ciuffreda, L, Iacovelli, R, Ferraù, F, Taibi, E, Bracarda, S, Porta, C, Galligioni, E & Contu, A 2014, 'Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting', Future Oncology, vol. 10, no. 10, pp. 1741-1750. https://doi.org/10.2217/fon.14.48
Procopio, Giuseppe ; Derosa, Lisa ; Gernone, Angela ; Morelli, Franco ; Sava, Teodoro ; Zustovich, Fable ; De Giorgi, Ugo ; Ferrari, Vittorio ; Sabbatini, Roberto ; Gasparro, Donatello ; Felici, Alessandra ; Burattini, Luciano ; Calvani, Nicola ; Lo Re, Giovanni ; Banna, Giuseppe ; Pia Brizzi, Maria ; Rizzo, Mimma ; Ciuffreda, Libero ; Iacovelli, Roberto ; Ferraù, Francesco ; Taibi, Eleonora ; Bracarda, Sergio ; Porta, Camillo ; Galligioni, Enzo ; Contu, Antonio. / Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. In: Future Oncology. 2014 ; Vol. 10, No. 10. pp. 1741-1750.
@article{704a6bd01c3e4582bdb7ad7b96fc84c1,
title = "Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting",
abstract = "Aim: The Italian Retrospective Analysis of Sorafenib as First or Second Target Therapy study assessed the efficacy and safety of sorafenib in metastatic renal cell carcinoma patients treated in the community. Patients & methods: Patients receiving first- or second-line single-agent sorafenib between January 2008 and December 2010 were eligible. Retrospective data collection started in 2012 and covers at least 1-year follow-up. The primary end point was overall survival (OS). Results: Median OS was 17.2 months (95{\%} CI: 15.5-19.6): 19.9 months (95{\%} CI: 15.9-25.3) in patients treated with first-line sorafenib and 16.3 months (95{\%} CI: 13.1-18.2) with second-line sorafenib. Overall median (95{\%} CI) progression-free survival was 5.9 months (95{\%} CI: 4.9-6.7): 6.6 (95{\%} CI: 4.9-9.3) and 5.3 months (95{\%} CI: 4.3-6.0) in first- and second-line patients, respectively. Conclusion: The efficacy and safety of sorafenib in routine community practice was generally good, especially in relation to OS in patients treated in the second line, where results were similar to those seen in recent prospective clinical trials.",
keywords = "community practice, renal cell carcinoma, second-line treatment, sorafenib, targeted agents, tyrosine kinase inhibitors",
author = "Giuseppe Procopio and Lisa Derosa and Angela Gernone and Franco Morelli and Teodoro Sava and Fable Zustovich and {De Giorgi}, Ugo and Vittorio Ferrari and Roberto Sabbatini and Donatello Gasparro and Alessandra Felici and Luciano Burattini and Nicola Calvani and {Lo Re}, Giovanni and Giuseppe Banna and {Pia Brizzi}, Maria and Mimma Rizzo and Libero Ciuffreda and Roberto Iacovelli and Francesco Ferra{\`u} and Eleonora Taibi and Sergio Bracarda and Camillo Porta and Enzo Galligioni and Antonio Contu",
year = "2014",
month = "8",
day = "1",
doi = "10.2217/fon.14.48",
language = "English",
volume = "10",
pages = "1741--1750",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "10",

}

TY - JOUR

T1 - Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting

AU - Procopio, Giuseppe

AU - Derosa, Lisa

AU - Gernone, Angela

AU - Morelli, Franco

AU - Sava, Teodoro

AU - Zustovich, Fable

AU - De Giorgi, Ugo

AU - Ferrari, Vittorio

AU - Sabbatini, Roberto

AU - Gasparro, Donatello

AU - Felici, Alessandra

AU - Burattini, Luciano

AU - Calvani, Nicola

AU - Lo Re, Giovanni

AU - Banna, Giuseppe

AU - Pia Brizzi, Maria

AU - Rizzo, Mimma

AU - Ciuffreda, Libero

AU - Iacovelli, Roberto

AU - Ferraù, Francesco

AU - Taibi, Eleonora

AU - Bracarda, Sergio

AU - Porta, Camillo

AU - Galligioni, Enzo

AU - Contu, Antonio

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Aim: The Italian Retrospective Analysis of Sorafenib as First or Second Target Therapy study assessed the efficacy and safety of sorafenib in metastatic renal cell carcinoma patients treated in the community. Patients & methods: Patients receiving first- or second-line single-agent sorafenib between January 2008 and December 2010 were eligible. Retrospective data collection started in 2012 and covers at least 1-year follow-up. The primary end point was overall survival (OS). Results: Median OS was 17.2 months (95% CI: 15.5-19.6): 19.9 months (95% CI: 15.9-25.3) in patients treated with first-line sorafenib and 16.3 months (95% CI: 13.1-18.2) with second-line sorafenib. Overall median (95% CI) progression-free survival was 5.9 months (95% CI: 4.9-6.7): 6.6 (95% CI: 4.9-9.3) and 5.3 months (95% CI: 4.3-6.0) in first- and second-line patients, respectively. Conclusion: The efficacy and safety of sorafenib in routine community practice was generally good, especially in relation to OS in patients treated in the second line, where results were similar to those seen in recent prospective clinical trials.

AB - Aim: The Italian Retrospective Analysis of Sorafenib as First or Second Target Therapy study assessed the efficacy and safety of sorafenib in metastatic renal cell carcinoma patients treated in the community. Patients & methods: Patients receiving first- or second-line single-agent sorafenib between January 2008 and December 2010 were eligible. Retrospective data collection started in 2012 and covers at least 1-year follow-up. The primary end point was overall survival (OS). Results: Median OS was 17.2 months (95% CI: 15.5-19.6): 19.9 months (95% CI: 15.9-25.3) in patients treated with first-line sorafenib and 16.3 months (95% CI: 13.1-18.2) with second-line sorafenib. Overall median (95% CI) progression-free survival was 5.9 months (95% CI: 4.9-6.7): 6.6 (95% CI: 4.9-9.3) and 5.3 months (95% CI: 4.3-6.0) in first- and second-line patients, respectively. Conclusion: The efficacy and safety of sorafenib in routine community practice was generally good, especially in relation to OS in patients treated in the second line, where results were similar to those seen in recent prospective clinical trials.

KW - community practice

KW - renal cell carcinoma

KW - second-line treatment

KW - sorafenib

KW - targeted agents

KW - tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84907940395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907940395&partnerID=8YFLogxK

U2 - 10.2217/fon.14.48

DO - 10.2217/fon.14.48

M3 - Article

C2 - 24641206

AN - SCOPUS:84907940395

VL - 10

SP - 1741

EP - 1750

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 10

ER -